Gerald Shulman, MD, PhD: The Future of Diabetes Treatments

December 9, 2020
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

Strategic Alliance Partnership | <b>The Metabolic Institute of America</b>

Dr. Gerald Shulman discusses how diabetes can eventually be reversed.

Could addressing insulin resistance in patients reverse the course of diabetes while reducing the risk of comorbid cardiovascular events and chronic kidney disease?

New research presented during the 18th World Congress of Insulin Resistance Diabetes & Cardiovascular (WCIRDC) Online CME Conference presented by the Metabolic Institute of America (TMIOA), shows the particular role of diacylglycerol and acetyl-CoAin might play in insulin resistance.

In an interview with HCPLive®, Gerald Shulman, MD, PhD, George R. Cowgill Professor of Medicine and Cellular & Molecular Physiology at Yale, explained how more insight into these lipids could shed light on why patients suffer from insulin resistance and what can be done to avoid this issue.

Shulman said a better explanation on why insulin resistance occurs ultimately will yield better diabetes treatments for patients and reverse diabetes.

This hypothesis, Shulman said, has been proven thus far in multiple animal models. However, there are not many agents currently available that would achieve this goal.

Recent studies show it is diacylglycerol that trigger PKC activation, leading to blocks to insulin signaling and insulin action.

Shulman previously explained how fixing insulin resistance could have an impact at reducing some of the cardiovascular and kidney comorbidities commonly associated with type 2 diabetes.